Telomir Pharmaceuticals (NASDAQ: TELO) has published peer-reviewed preclinical data in Advances in Redox Research demonstrating that its lead compound, Telomir-Zn, delivered dose-dependent survival improvements and multiple therapeutic benefits in a Wilson’s disease model. The findings, announced in a press release, showed reduced oxidative stress, lower hepatic copper burden, and improved liver function markers, supporting the compound’s biological activity in this rare genetic disorder.
Wilson’s disease is a condition characterized by copper accumulation in the body, leading to liver and neurological damage. Current treatments include chelation therapy and zinc supplementation, but they have limitations. Telomir-Zn, which modulates intracellular metal homeostasis and redox balance, could offer a novel approach. The preclinical results expand the company’s scientific validation beyond its lead triple-negative breast cancer program, which is advancing toward Phase 1/2 clinical initiation.
According to the press release, Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics targeting fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. Telomir-1 (Telomir-Zn) has shown activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability. The company’s stock trades on the Nasdaq under the ticker TELO, and more information is available in its newsroom at https://ibn.fm/TELO.
The publication in a peer-reviewed journal adds credibility to the findings, which could pave the way for further development in Wilson’s disease. However, the data are preclinical, and human studies will be needed to confirm efficacy and safety. The implications are significant for patients with Wilson’s disease, who may benefit from a targeted therapy that addresses underlying metal dysregulation. For Telomir, positive results in a second indication could de-risk its platform and attract partnership or investment interest.
The full press release is available at https://ibn.fm/fOSNo. Telomir Pharmaceuticals continues to focus on its lead oncology program while exploring additional applications for Telomir-Zn. The company is headquartered in the United States and can be followed via its investor relations channels.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Telomir Pharmaceuticals Reports Preclinical Data Supporting Telomir-Zn for Wilson’s Disease.